Dyne Therapeutics Announces FDA Breakthrough Therapy
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S....
Breakthrough therapy targets aggressive bladder cancer variant
Bladder tumors that have been excluded from clinical trials have a few...
Biotech Student Crafts Market Strategy for Breakthrough Pediatric Cancer Therapy
By Dave DeFuscoAt the recent Graduate Symposium of Science, Health and Technology, Jenny Maharjan, a student in the M.S. in Biotechnology Management...
